About Serine incorporator 5
Serine incorporator 5 (SERINC5) is a protein
from Homo sapiens identified by UniProt accession
Q86VE9, 423 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Serine incorporator 5 |
|---|
| UniProt accession | Q86VE9 |
|---|
| Gene | SERINC5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 423 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- PHF-tau measurement · score 0.33
- hair colour measurement · score 0.32
- cholesteatoma of external ear · score 0.28
- amyloid-beta measurement · score 0.23
- refractive error measurement · score 0.13
- infection · score 0.08
- infect · score 0.08
- metabolite measurement · score 0.07
- blood protein measurement · score 0.06
- drug use measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86VE9-F1 | alphafold | PREDICTED | 77.65 | — |
Amino-acid sequence (423 residues)
MSAQCCAGQL ACCCGSAGCS LCCDCCPRIR QSLSTRFMYA LYFILVVVLC CIMMSTTVAH KMKEHIPFFE DMCKGIKAGD TCEKLVGYSA VYRVCFGMAC FFFIFCLLTL KINNSKSCRA HIHNGFWFFK LLLLGAMCSG AFFIPDQDTF LNAWRYVGAV GGFLFIGIQL LLLVEFAHKW NKNWTAGTAS NKLWYASLAL VTLIMYSIAT GGLVLMAVFY TQKDSCMENK ILLGVNGGLC LLISLVAISP WVQNRQPHSG LLQSGVISCY VTYLTFSALS SKPAEVVLDE HGKNVTICVP DFGQDLYRDE NLVTILGTSL LIGCILYSCL TSTTRSSSDA LQGRYAAPEL EIARCCFCFS PGGEDTEEQQ PGKEGPRVIY DEKKGTVYIY SYFHFVFFLA SLYVMMTVTN WFNHVRSAFH LLP
Explore Serine incorporator 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets